The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype

Drug Metabolism and Disposition

Volumn 32, Issue 5, 2004, Pages 484-489

  Sandberg, Mia ^a   Johansson, Inger ^a   Christensen, Magnus ^a   Rane, Anders ^a   Eliasson, Erik ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; LOSARTAN; LOSARTAN POTASSIUM; ORAL CONTRACEPTIVE AGENT; WARFARIN;

ADULT; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME METABOLISM; EXON; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTRON; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; LINEAR MODELS; MALE; PHENOTYPE; VARIATION (GENETICS);

EID: 2042478041     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.5.484     Document Type: Article

References (26)

1. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z, Nacak M, and Roots I (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409-415.
2. Caraco Y, Muszkat M, and Wood AJ (2001) Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11:587-596.
3. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, and Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517-528.
4. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, and Maurel P (2002) Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 277:209-217.
5. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
6. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, et al. (2001) The predictive value of MDR1, CYP2C9 and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1:204-210.
7. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, and Bertino JS Jr (2001) Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 41:715-722.
8. Kimura M, Ieiri I, Mamiya K, Urae A, and Higuchi S (1998) Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Ther Drug Monit 20:243-247.
9. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, and Brockmoller J (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109.
10. Laine K, Yasar U, Widen J, and Tybring G (2003) A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81.
11. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, and Goldstein JA (2002) Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther 72:562-571.
12. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
13. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, and Castell JV (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393:308-315.
14. Sandberg M, Yasar U, Stromberg P, Hoog JO, and Eliasson E (2002) Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54: 423-429.
15. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, and Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450.
16. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, and Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710.
17. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, and Otsubo K (2001) Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 70:175-182.
18. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, and Shin JG (2002) Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12:111-119.
19. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen and diclofenac by human liver microsomes. Biochem Pharmacol 56:243-251.
20. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK, and Wennerholm A (2002a) Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations. Eur J Clin Pharmacol 58:555-558.
21. Yasar U, Dahl ML, Christensen M, and Eliasson E (2002b) Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 54:183-185.
22. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, and Dahl ML (2002c) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98.
23. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, and Rane A (2002d) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25-28.
24. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, and Sjöqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population [published erratum appears in Biochem Biophys Res Commun (1999) 258:227]. Biochem Biophys Res Commun 254:628-631.
25. Yasar Ü, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjöqvist F, and Dahl M-L (2001a) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57:729-735.
26. Yasar Ü, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, and Eliasson E (2001b) The role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051-1056.